Antibody data
- Antibody Data
- Antigen structure
- References [0]
- Comments [0]
- Validations
- ELISA [1]
- Flow cytometry [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- Ab183440 - Provider product page
- Provider
- Aladdin Scientific
- Product name
- Teneliximab (anti-CD40)
- Antibody type
- Recombinant
- Description
- Teneliximab (anti-CD40) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (anti-CD40) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion.Purity>95% (SDS-PAGE&SEC)Endotoxin Level< 1.0EU/mg
- Reactivity
- Human
- Conjugate
- Unconjugated
- Vial size
- 100_g,10mg,1mg,5mg
- Concentration
- Lot by Lot
- Storage
- Store at -80_ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
No comments: Submit comment
Supportive validation
- Submitted by
- Aladdin Scientific (provider)
- Main image
- Experimental details
- Teneliximab (anti-CD40) (Ab183440) - ELISA Immobilized Recombinant Human CD40 Protein (rp144000) at 1.0 μg/mL can bind Teneliximab (anti-CD40) (Ab183440) with the EC50 of 11.50 ng/mL.
Supportive validation
- Submitted by
- Aladdin Scientific (provider)
- Main image
- Experimental details
- Teneliximab (anti-CD40) (Ab183440) - Flow Cytometry Flow Cytometry analysis of Raji cells labelling CD40 (red) with Teneliximab (anti-CD40) (Ab183440). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
- Submitted by
- Aladdin Scientific (provider)
- Main image
- Experimental details
- Teneliximab (anti-CD40) (Ab183440) - Flow Cytometry Flow Cytometry analysis of U-2OS cells labelling CD40 (red) with Teneliximab (anti-CD40) (Ab183440). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.